Jefferies' Cytokinetics (CYTK) Investor Survey Reveals Approval and Market Opportunity Expectations

Jefferies analyst Akash Tewari reiterated a Buy rating and $75.00 price target on Cytokinetics (NASDAQ: CYTK) after conducting an investor survey on the set up for CYTK/BMY heading into mava's PDUFA day, April 28th and learning approval is expected with median estimated peak sales of $2Bn for mava and ~$1.6Bn for Aficamten.

The analyst stated "Overall, ~86% (44/51) of responders think mava will get approved on April 28th while the other ~14% expect FDA to delay decision or extend review. None of our responders believes mava gets a CRL. Based on responses we collected, quarterly monitoring for LVEF drops (selected by ~69% of responders), PK/PD-guided dose titration (selected by ~47% of responders) and quarterly blood draws (selected by ~37% of responders) are all considered unfavorable REMS for mava".

For an analyst ratings summary and ratings history on Cytokinetics click here. For more ratings news on Cytokinetics click here.

Shares of Cytokinetics closed at $36.50 yesterday.

You May Also Be Interested In

• Cytokinetics (CYTK) PT Raised to $113 at RBC Capital
• Sherwin-Williams (SHW) PT Lowered to $392 at RBC Capital
• Carlisle (CSL) PT Lowered to $355 at DA Davidson